カテゴリー： Market Monitor Global, 世界, 医療/バイオ

膀胱がん標的薬の世界市場見通し2023年-2029年

◆英語タイトル：Bladder Cancer Targeted Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5720）◆商品コード：MMG23JU5720
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：66
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥487,500見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥633,750見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥731,250見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Bladder Cancer Targeted Drug Market 調査レポートは次の情報を含め、グローバルにおけるの膀胱がん標的薬市場規模と予測を収録しています。・世界の膀胱がん標的薬市場：売上、2018年-2023年、2024年-2029年
・世界の膀胱がん標的薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の膀胱がん標的薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アテゾリズマブ（テセントリク）」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

膀胱がん標的薬のグローバル主要企業は、Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、膀胱がん標的薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の膀胱がん標的薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の膀胱がん標的薬市場：タイプ別市場シェア、2022年
・アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他

世界の膀胱がん標的薬市場：用途別、2018年-2023年、2024年-2029年
世界の膀胱がん標的薬市場：用途別市場シェア、2022年
・病院、小売薬局、その他

世界の膀胱がん標的薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の膀胱がん標的薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における膀胱がん標的薬のグローバル売上、2018年-2023年
・主要企業における膀胱がん標的薬のグローバル売上シェア、2022年
・主要企業における膀胱がん標的薬のグローバル販売量、2018年-2023年
・主要企業における膀胱がん標的薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciences

*************************************************************

・調査・分析レポートの概要
膀胱がん標的薬市場の定義
市場セグメント
世界の膀胱がん標的薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の膀胱がん標的薬市場規模
世界の膀胱がん標的薬市場規模：2022年 VS 2029年
世界の膀胱がん標的薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの膀胱がん標的薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の膀胱がん標的薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：アテゾリズマブ（テセントリク）、アベルマブ（バベンシオ）、エルダフィチニブ（バルバーサ）、その他
膀胱がん標的薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局、その他
膀胱がん標的薬の用途別グローバル売上・予測

・地域別市場分析
地域別膀胱がん標的薬市場規模 2022年と2029年
地域別膀胱がん標的薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Pfizer、 Merck KGaA、 Roche、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Merck & Co.、 Gilead Sciences
...

Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
This report aims to provide a comprehensive presentation of the global market for Bladder Cancer Targeted Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bladder Cancer Targeted Drug. This report contains market size and forecasts of Bladder Cancer Targeted Drug in global, including the following market information:
Global Bladder Cancer Targeted Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Bladder Cancer Targeted Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Atezolizumab (Tecentriq) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Bladder Cancer Targeted Drug include Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co. and Gilead Sciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bladder Cancer Targeted Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bladder Cancer Targeted Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, by Type, 2022 (%)
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Global Bladder Cancer Targeted Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Bladder Cancer Targeted Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bladder Cancer Targeted Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Bladder Cancer Targeted Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bladder Cancer Targeted Drug, market overview.
Chapter 2: Global Bladder Cancer Targeted Drug market size in revenue.
Chapter 3: Detailed analysis of Bladder Cancer Targeted Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bladder Cancer Targeted Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Bladder Cancer Targeted Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Bladder Cancer Targeted Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Bladder Cancer Targeted Drug Overall Market Size
2.1 Global Bladder Cancer Targeted Drug Market Size: 2022 VS 2029
2.2 Global Bladder Cancer Targeted Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Bladder Cancer Targeted Drug Players in Global Market
3.2 Top Global Bladder Cancer Targeted Drug Companies Ranked by Revenue
3.3 Global Bladder Cancer Targeted Drug Revenue by Companies
3.4 Top 3 and Top 5 Bladder Cancer Targeted Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Bladder Cancer Targeted Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bladder Cancer Targeted Drug Players in Global Market
3.6.1 List of Global Tier 1 Bladder Cancer Targeted Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Bladder Cancer Targeted Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Bladder Cancer Targeted Drug Market Size Markets, 2022 & 2029
4.1.2 Atezolizumab (Tecentriq)
4.1.3 Avelumab (Bavencio)
4.1.4 Erdafitinib (Balversa)
4.1.5 Other
4.2 By Type – Global Bladder Cancer Targeted Drug Revenue & Forecasts
4.2.1 By Type – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
4.2.2 By Type – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
4.2.3 By Type – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Bladder Cancer Targeted Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Bladder Cancer Targeted Drug Revenue & Forecasts
5.2.1 By Application – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
5.2.2 By Application – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
5.2.3 By Application – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Bladder Cancer Targeted Drug Market Size, 2022 & 2029
6.2 By Region – Global Bladder Cancer Targeted Drug Revenue & Forecasts
6.2.1 By Region – Global Bladder Cancer Targeted Drug Revenue, 2018-2023
6.2.2 By Region – Global Bladder Cancer Targeted Drug Revenue, 2024-2029
6.2.3 By Region – Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Bladder Cancer Targeted Drug Revenue, 2018-2029
6.3.2 US Bladder Cancer Targeted Drug Market Size, 2018-2029
6.3.3 Canada Bladder Cancer Targeted Drug Market Size, 2018-2029
6.3.4 Mexico Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Bladder Cancer Targeted Drug Revenue, 2018-2029
6.4.2 Germany Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.3 France Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.4 U.K. Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.5 Italy Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.6 Russia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.7 Nordic Countries Bladder Cancer Targeted Drug Market Size, 2018-2029
6.4.8 Benelux Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Bladder Cancer Targeted Drug Revenue, 2018-2029
6.5.2 China Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.3 Japan Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.4 South Korea Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.5 Southeast Asia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.5.6 India Bladder Cancer Targeted Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Bladder Cancer Targeted Drug Revenue, 2018-2029
6.6.2 Brazil Bladder Cancer Targeted Drug Market Size, 2018-2029
6.6.3 Argentina Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Bladder Cancer Targeted Drug Revenue, 2018-2029
6.7.2 Turkey Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.3 Israel Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Bladder Cancer Targeted Drug Market Size, 2018-2029
6.7.5 UAE Bladder Cancer Targeted Drug Market Size, 2018-2029
7 Bladder Cancer Targeted Drug Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Bladder Cancer Targeted Drug Major Product Offerings
7.1.4 Pfizer Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Company Summary
7.2.2 Merck KGaA Business Overview
7.2.3 Merck KGaA Bladder Cancer Targeted Drug Major Product Offerings
7.2.4 Merck KGaA Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.2.5 Merck KGaA Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Bladder Cancer Targeted Drug Major Product Offerings
7.3.4 Roche Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 Astellas
7.4.1 Astellas Company Summary
7.4.2 Astellas Business Overview
7.4.3 Astellas Bladder Cancer Targeted Drug Major Product Offerings
7.4.4 Astellas Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.4.5 Astellas Key News & Latest Developments
7.5 Janssen Biotech
7.5.1 Janssen Biotech Company Summary
7.5.2 Janssen Biotech Business Overview
7.5.3 Janssen Biotech Bladder Cancer Targeted Drug Major Product Offerings
7.5.4 Janssen Biotech Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.5.5 Janssen Biotech Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Bladder Cancer Targeted Drug Major Product Offerings
7.6.4 Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Bladder Cancer Targeted Drug Major Product Offerings
7.7.4 Merck & Co. Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Bladder Cancer Targeted Drug Major Product Offerings
7.8.4 Gilead Sciences Bladder Cancer Targeted Drug Revenue in Global Market (2018-2023)
7.8.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Bladder Cancer Targeted Drug Market Opportunities & Trends in Global Market
Table 2. Bladder Cancer Targeted Drug Market Drivers in Global Market
Table 3. Bladder Cancer Targeted Drug Market Restraints in Global Market
Table 4. Key Players of Bladder Cancer Targeted Drug in Global Market
Table 5. Top Bladder Cancer Targeted Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Bladder Cancer Targeted Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Bladder Cancer Targeted Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Bladder Cancer Targeted Drug Product Type
Table 9. List of Global Tier 1 Bladder Cancer Targeted Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Bladder Cancer Targeted Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Bladder Cancer Targeted Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Bladder Cancer Targeted Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Bladder Cancer Targeted Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Bladder Cancer Targeted Drug Product Offerings
Table 32. Pfizer Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Merck KGaA Company Summary
Table 35. Merck KGaA Bladder Cancer Targeted Drug Product Offerings
Table 36. Merck KGaA Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Merck KGaA Key News & Latest Developments
Table 38. Roche Company Summary
Table 39. Roche Bladder Cancer Targeted Drug Product Offerings
Table 40. Roche Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Roche Key News & Latest Developments
Table 42. Astellas Company Summary
Table 43. Astellas Bladder Cancer Targeted Drug Product Offerings
Table 44. Astellas Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Astellas Key News & Latest Developments
Table 46. Janssen Biotech Company Summary
Table 47. Janssen Biotech Bladder Cancer Targeted Drug Product Offerings
Table 48. Janssen Biotech Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Janssen Biotech Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Summary
Table 51. Bristol-Myers Squibb Bladder Cancer Targeted Drug Product Offerings
Table 52. Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol-Myers Squibb Key News & Latest Developments
Table 54. Merck & Co. Company Summary
Table 55. Merck & Co. Bladder Cancer Targeted Drug Product Offerings
Table 56. Merck & Co. Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Merck & Co. Key News & Latest Developments
Table 58. Gilead Sciences Company Summary
Table 59. Gilead Sciences Bladder Cancer Targeted Drug Product Offerings
Table 60. Gilead Sciences Bladder Cancer Targeted Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Bladder Cancer Targeted Drug Segment by Type in 2022
Figure 2. Bladder Cancer Targeted Drug Segment by Application in 2022
Figure 3. Global Bladder Cancer Targeted Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Bladder Cancer Targeted Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Bladder Cancer Targeted Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Bladder Cancer Targeted Drug Revenue in 2022
Figure 8. By Type - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 16. US Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 20. Germany Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 28. China Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Bladder Cancer Targeted Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Bladder Cancer Targeted Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck KGaA Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Astellas Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Janssen Biotech Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol-Myers Squibb Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck & Co. Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Sciences Bladder Cancer Targeted Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 膀胱がん標的薬の世界市場見通し2023年-2029年(Bladder Cancer Targeted Drug Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 膀胱がん標的療法の世界市場見通し2023年-2029年
  • 筋層非浸潤性膀胱癌治療の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆